Advertisement

Hormones

, Volume 15, Issue 1, pp 35–44 | Cite as

Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome

  • Djuro MacutEmail author
  • Ivana Božić Antić
  • Jelica Bjekić-Macut
  • Dimitrios Panidis
  • Konstantinos Tziomalos
  • Danijela Vojnović Milutinović
  • Olivera Stanojlović
  • Biljana Kastratović-Kotlica
  • Milan Petakov
  • Nataša Milić
Research paper

Abstract

OBJECTIVE: There is a need for a simple and accurate method for the assessment of cardiovascular risk in polycystic ovary syndrome (PCOS). Lipid accumulation product (LAP) is based on the assessment of waist circumference and serum triglycerides that yield an estimation of lipid overaccumulation. We aimed to determine whether LAP is associated with metabolic syndrome (MetS) in Caucasian women with PCOS. DESIGN: We studied 222 women with PCOS who were diagnosed using the Rotterdam criteria. In all the subjects and controls, LAP was determined and the MetS was assessed using three different international criteria, NCEP-ATP III, IDF, and JIS. ROC curve and logistic regression analyses were performed to determine and analyze associations with the MetS. RESULTS: In the study population the prevalence of MetS was 16.2–19.4%. The cut-off value of 25.9 determined that LAP has the strongest association with MetS whichever international criteria are used, followed by HDL (NCEP-ATP III and JIS) and glucose (IDF). CONCLUSIONS: LAP is used as an independent clinical indicator for MetS in our PCOS women of Caucasian origin. The high diagnostic accuracy of LAP is superseding the need for the use of multiple clinical indicators for the assessment of lipid accumulation as a prerequisite for diagnosis of metabolic and cardiovascular diseases in PCOS women.

Key words

Lipid accumulation product Metabolic syndrome Polycystic ovary syndrome Triglycerides Waist circumference 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R, 1998 Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83: 3078–3082.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al, 1999 A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 84: 4006–4011.CrossRefPubMedGoogle Scholar
  3. 3.
    Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO, 2004 The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89: 2745–2749.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Diamanti-Kandarakis E, Dunaif A, 2012 Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 33: 981–1030.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J, 1999 Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22: 141–146.CrossRefPubMedGoogle Scholar
  6. 6.
    Legro RS, Kunselman AR, Dunaif A, 2001 Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 111: 607–613.CrossRefPubMedGoogle Scholar
  7. 7.
    Mani H, Levy MJ, Davies MJ, et al, 2013 Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study. Clin Endocrinol (Oxf) 78: 926–934.CrossRefGoogle Scholar
  8. 8.
    Cussons AJ, Watts GF, Burke V, Shaw JE, Zimmet PZ, Stuckey BG, 2008 Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Hum Reprod 23: 2352–2358.CrossRefPubMedGoogle Scholar
  9. 9.
    Gambineri A, Repaci A, Patton L, et al, 2009 Prominent role of low HDL-cholesterol in explaining the high prevalence of the metabolic syndrome in polycystic ovary syndrome. Nutr Metab Cardiovasc Dis 19: 797–804.CrossRefPubMedGoogle Scholar
  10. 10.
    Panidis D, Macut D, Tziomalos K, et al, 2013 Prevalence of metabolic syndrome in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 78: 586–592.CrossRefGoogle Scholar
  11. 11.
    Coviello AD, Legro RS, Dunaif A, 2006 Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 91: 492–497.CrossRefPubMedGoogle Scholar
  12. 12.
    Macut D, Damjanovic S, Panidis D, et al, 2006 Oxidised low-density lipoprotein concentration — early marker of an altered lipid metabolism in young women with PCOS. Eur J Endocrinol 155: 131–136.CrossRefPubMedGoogle Scholar
  13. 13.
    Kahn HS, 2005 The “lipid accumulation product” performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord 5: 26.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Taverna MJ, Martinez-Larrad MT, Frechtel GD, Serrano-Rios M, 2011 Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population. Eur J Endocrinol 164: 559–567.CrossRefPubMedGoogle Scholar
  15. 15.
    Wehr E, Gruber HJ, Giuliani A, Möller R, Pieber TR, Obermayer-Pietsch B, 2011 The lipid accumulation product is associated with impaired glucose tolerance in PCOS women. J Clin Endocrinol Metab 96: E986–990.CrossRefPubMedGoogle Scholar
  16. 16.
    Xiang S, Hua F, Chen L, Tang Y, Jiang X, Liu Z, 2013 Lipid accumulation product is related to metabolic syndrome in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 121: 115–118.CrossRefPubMedGoogle Scholar
  17. 17.
    Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). 2004 Hum Reprod 19: 41–47.CrossRefGoogle Scholar
  18. 18.
    Friedewald WT, Levy RI, Fredrickson DS, 1972 Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499–502.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Mathur RS, Moody LO, Landgrebe S, Williamson HO, 1981 Plasma androgens and sex hormone-binding globulin in the evaluation of hirsute females. Fertil Steril 35: 29–35.CrossRefPubMedGoogle Scholar
  20. 20.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, 1985 Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. 2002 Circulation 106: 3143–3421.Google Scholar
  22. 22.
    Alberti KG, Zimmet P, Shaw J, 2005 The metabolic syndrome—a new worldwide definition. Lancet 366: 1059–1062.CrossRefPubMedGoogle Scholar
  23. 23.
    Alberti KG, Eckel RH, Grundy SM, et al, 2009 Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640–1645.CrossRefPubMedGoogle Scholar
  24. 24.
    Hanley JA, McNeil BJ, 1983 A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148: 839–843.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Apridonidze T, Essah PA, Iuorno MJ, Nestler JE, 2005 Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90: 1929–1935.CrossRefPubMedGoogle Scholar
  26. 26.
    Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA, 2006 Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol 154: 141–145.CrossRefPubMedGoogle Scholar
  27. 27.
    Wijeyaratne CN, Seneviratne Rde A, Dahanayake S, et al, 2011 Phenotype and metabolic profile of South Asian women with polycystic ovary syndrome (PCOS): results of a large database from a specialist Endocrine Clinic. Hum Reprod 26: 202–213.CrossRefPubMedGoogle Scholar
  28. 28.
    Dewailly D, Contestin M, Gallo C, Catteau-Jonard S, 2010 Metabolic syndrome in young women with the polycystic ovary syndrome: revisiting the threshold for an abnormally decreased high-density lipoprotein cholesterol serum level. BJOG 117: 175–180.CrossRefPubMedGoogle Scholar
  29. 29.
    Alberti KG, Zimmet P, Shaw J, 2006 Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 23: 469–480.CrossRefPubMedGoogle Scholar
  30. 30.
    Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R, 2002 Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 26: 883–896.CrossRefPubMedGoogle Scholar
  31. 31.
    Van Pelt RE, Evans EM, Schechtman KB, Ehsani AA, Kohrt WM, 2002 Contributions of total and regional fat mass to risk for cardiovascular disease in older women. Am J Physiol Endocrinol Metab 282: E1023–1028.CrossRefPubMedGoogle Scholar
  32. 32.
    Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET, 2004 Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab 89: 2569–2575.CrossRefPubMedGoogle Scholar
  33. 33.
    Wiltgen D, Benedetto IG, Mastella LS, Spritzer PM, 2009 Lipid accumulation product index: a reliable marker of cardiovascular risk in polycystic ovary syndrome. Hum Reprod 24: 1726–1731.CrossRefPubMedGoogle Scholar
  34. 34.
    Lean ME, Han TS, Morrison CE, 1995 Waist circumference as a measure for indicating need for weight management. BMJ 311: 158–161.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Underwood PM, 2004 Cardiovascular risk, the metabolic syndrome and the hypertriglyceridaemic waist. Curr Opin Lipidol 15: 495–497.CrossRefPubMedGoogle Scholar
  36. 36.
    McGee DL, 2005 Body mass index and mortality: a meta-analysis based on person-level data from twenty-six observational studies. Ann Epidemiol 15: 87–97.CrossRefPubMedGoogle Scholar
  37. 37.
    Macut D, Panidis D, Glisic B, et al, 2008 Lipid and lipoprotein profile in women with polycystic ovary syndrome. Can J Physiol Pharmacol 86: 199–204.CrossRefPubMedGoogle Scholar
  38. 38.
    Nofer JR, van der Giet M, Tolle M, et al, 2004 HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 113: 569–581.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Bonora E, Kiechl S, Willeit J, et al, 1998 Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 47: 1643–1649.CrossRefPubMedGoogle Scholar
  40. 40.
    Nesto RW, 2003 The relation of insulin resistance syndromes to risk of cardiovascular disease. Rev Cardiovasc Med 4: Suppl 6: 11–18.Google Scholar
  41. 41.
    Ehrmann DA, Liljenquist DR, Kasza K, et al; PCOS/Troglitazone Study Group, 2006 Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 91: 48–53.CrossRefPubMedGoogle Scholar
  42. 42.
    Taieb J, Mathian B, Millot F, et al, 2003 Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem 49: 1381–1395.CrossRefPubMedGoogle Scholar
  43. 43.
    Hahn S, Kuehnel W, Tan S, et al, 2007 Diagnostic value of calculated testosterone indices in the assessment of polycystic ovary syndrome. Clin Chem Lab Med 45: 202–207.CrossRefPubMedGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2016

Authors and Affiliations

  • Djuro Macut
    • 1
    Email author
  • Ivana Božić Antić
    • 1
  • Jelica Bjekić-Macut
    • 2
  • Dimitrios Panidis
    • 3
  • Konstantinos Tziomalos
    • 4
  • Danijela Vojnović Milutinović
    • 5
  • Olivera Stanojlović
    • 6
  • Biljana Kastratović-Kotlica
    • 7
  • Milan Petakov
    • 1
  • Nataša Milić
    • 8
  1. 1.Clinic for Endocrinology, Diabetes and Diseases of Metabolism, Faculty of MedicineUniversity of BelgradeBelgradeSerbia
  2. 2.CHC Bežanijska kosaBelgradeSerbia
  3. 3.Division of Endocrinology and Human Reproduction, Second Department of Obstetrics and GynecologyAristotle University of Thessaloniki, Hippokration HospitalThessalonikiGreece
  4. 4.First Propedeutic Department of Internal MedicineAristotle University of Thessaloniki, AHEPA HospitalThessalonikiGreece
  5. 5.Department of Biochemistry, Institute for Biological Research “Siniša Stanković”University of BelgradeBelgradeSerbia
  6. 6.Institute of Medical Physiology, Faculty of MedicineUniversity of BelgradeBelgradeSerbia
  7. 7.Clinic for Obstetrics and Gynecology, Faculty of MedicineUniversity of BelgradeBelgradeSerbia
  8. 8.Institute of Medical Statistics, Faculty of MedicineUniversity of BelgradeBelgradeSerbia

Personalised recommendations